Abstract
Background:
Acute lung injury (ALI) is one of the most prevalent respiratory diseases globally. Jingfang Baidu Powder (JF) is a clinically approved traditional Chinese medicine used for treating respiratory infectious diseases. However, its effects and mechanism in the context of ALI remain poorly understood. In this study, we investigated the potential of JF to alleviate ALI by reducing inflammation and necroptosis of lung epithelial cells.
Methods:
The effects of JF on ALI were evaluated using an integrative pharmacological strategy. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was employed to identify the bioactive compounds of JF present in the serum of ALI mice, which are responsible for its therapeutic efficacy in treating ALI. ALI mouse models were established by the nasal drops of Poly (I∶C) over 3 days, followed by, intragastric administration of JF four times. We investigated Changes in lung function, inflammatory cytokines, pathological morphology of lung tissue, mitochondrial indicators, both transcriptomic and metabolomic profiles of the lung tissue, and necroptosis of lung epithelial cells.
Results:
JF reduced airway resistance in ALI mice (p < 0.01) and respiratory frequency (p < 0.05); it lowered the levels of TNF-α in NLF, BALF, and serum (p < 0.05 or p < 0.01) and the content of IL-6 in NLF (p < 0.01), while improving the pathological damage of alveolar epithelial cells and mitochondria in ALI mice. Transcriptomics analysis revealed that JF potentially inhibits necroptosis, with seven constituents, notably hesperidin, identified as the putative active components of JF. Metabolomics analysis demonstrated that JF facilitated pulmonary epithelial cell repair through multifaceted modulation of metabolic pathways. Mechanistic validation indicates that JF can reduce the levels of NEC-related factors LDH and IL-18 in BALF (p < 0.05 or p < 0.01), as well as decrease the protein levels of p-MLKL and GSDME in lung tissue and the ratio of p-MLKL to MLKL (p < 0.05 or p < 0.01). Additionally, both JF and hesperidin can reduce NEC in A549 cells (p < 0.05 or p < 0.01).
Conclusion:
JF can ameliorate ALI through various mechanisms, including its anti-inflammatory activity, inhibition of necroptosis, and enhancement of mitochondrial bioenergetics to promote ATP biosynthesis.
1 Introduction
Acute lung injury (ALI) and its severe manifestation, acute respiratory distress syndrome (ARDS), represent a significant global health challenge with persistently high mortality rates, particularly among critically ill patients suffering from trauma, sepsis, or infectius diseases worldwide (; ). Clinically characterized by refractory hypoxemia, progressive dyspnea, and pulmonary edema, ALI/ARDS pathogenesis involves complex interactions between uncontrolled pulmonary inflammation, disruption of alveolar-capillary barrier integrity, and subsequent cytokine storm-induced organ dysfunction. The devastating impact of these conditions was starkly illustrated during the COVID-19 pandemic, wherein SARS-CoV-2-mediated ARDS accounted for approximately 7 million deaths globally, underscoring the urgent need for effective therapeutic interventions (; ). Inhibiting the progression of ALI is considered an effective strategy for preventing ARDS. Despite extensive research, therapeutic advances for ALI remain limited, with no pharmacological interventions demonstrating definitive clinical efficacy to date. Several studies have indicated that certain drugs, including glucocorticoids, can ameliorate ALI (). However, large-scale clinical trials have shown their ineffectiveness in preventing progression to ARDS or reducing long-term mortality in patients who are hypoxic but do not requiring ventilatory support (; ). The therapeutic impasse is further compounded by the multifactorial nature of ALI pathophysiology, characterized by a self-amplifying cascade involving immune cell activation, endothelial barrier disrupting, necroptotic alveolar epithelial injury, and cellular energy metabolism dysregulation (). Notably, recent systems biology approaches have positioned mitochondrial dysfunction as a central driver of ALI progression, wherein bioenergetic failure through suppressed oxidative phosphorylation, ROS-mediated amplified inflammation and impaired mitophagy-driven quality control collectively perpetuate tissue damage (). These emerging mechanisms highlight potential therapeutic targets at the intersection of immunometabolism and cellular homeostasis.
The lack of targeted therapies necessitates innovative approaches that simultaneously address multiple pathogenic cascades. Traditional Chinese medicine (TCM) formulations, with their inherent poly-pharmacological properties, present promising candidates for such multi-target interventions. However, rigorous scientific verification of their mechanisms remains critical. In this context, our study investigates the therapeutic potential of Jingfang Baidu Powder (JF) against ALI, focusing on its potential effects on inflammatory modulation and mitochondrial homeostasis restoration.
JF is a well-known TCM, extensively prescribed for treating respiratory tract infection (). It originates from the classic TCM text < She Sheng Zhong Miao Fang>, which was authored by Shiche Zhang (). JF consisted of Schizonepeta tenuifolia Briq. (jingjie), Saposhnikovia divaricata (Turcz.) Schischk. (fangfeng), Notopterygium incisum Ting ex H. T. Chang (qianghuo), Angelica pubescens Maxim. f. biserrata Shan et Yuan (duhuo), Bupleurum chinense DC. (chaihu), Peucedanum praeruptorum Dunn (qianhu), Ligusticum chuanxiong Hort. (chuanxiong), Citrus aurantium L. (zhiqiao), Poria cocos (Schw.) Wolf. (fuling), Platycodon grandiflorum (Jacq.) A. DC. (jiegeng) and Glycyrrhiza uralensis Fisch. (gancao) (Figure 1). According to the theory of TCM, JF has a certain potential value of analgesic and antipyretic effect through sweating and dispelling exogenous evils. Clinical reports indicate that JF exhibits anti-inflammatory, anti-viral, and immune regulatory effects (). Furthermore, JF is suitable for use in children, pregnant women, and other populations requiring cautious medication, owing to its minimal side effects. In basic research, Professor Zhang demonstrated that JF granules alleviate bleomycin-induced () ALI by regulating the PI3K/Akt/mTOR signaling pathway (). Additionally, JF has also been successfully utilized to treat upper respiratory infections caused by influenza A and has been identified as a potential inhibitor of SARS-CoV-2 (). However, the role of JF in ALI remains poorly understood. The present research aims to elucidate the effects of JF in alleviating ALI and to explore the underlying mechanisms. We analyzed the serum components of JF in a mouse model of ALI, and employed transcriptomics and metabolomics to investigate the material basis and molecular mechanisms by which JF exerts its effects against ALI.
FIGURE 1
2 Materials and methods
2.1 Chemicals and regents
Dexamethasone (Dex, LB2269) was obtained from Zhejiang Xianju Pharmaceutical Co., Ltd. MLKL Mouse McAb (66675-1-Ig), DFNA5/GSDME Rabbit PolyAb (13075-1-AP), HRP-conjugated Beta Actin Monoclonal antibody (HRP-66009), HRP-conjugated Affinipure Goat Anti-Rabbit IgG (H + L) (SA00001-2), CoraLite 488-conjugated Goat Anti-Rabbit IgG (H + L), HRP-conjugated Affinipure Goat Anti-Mouse IgG (H + L) (SA00001-1), BCA Protein Assay Kit (PK10026), Hesperidin (CM00691) and Necrostatin-1 (CM00423-) were purchased from Proteintech Group, Inc. Anti-MLKL (phospho S345) antibody (ab196436) was obtained from Abcam Co. Polyinosinic-polycytidylic acid salt (poly (I∶C), PIC, P1530) was purchased from Sigma-Aldrich Trading Co.,Ltd. RIPA lysis buffer (R0010), Protein Phosphatase inhibitor (All-in one, 100×) (P1260), Mounting Medium, antifading (with DAPl) (S2110) and electron microscope fixative (G1102) were purchased from Beijing Solarbio Science & Technology Co., Ltd. Triton X-100 Solution (ST797) and Necroptosis Inducer Kit with TSZ (C1058S) were obtained from Beyotime Biotech Inc commit. CellTiter96® AQueous One Solution Cell Proliferation Assay was obtained from Promega Biotech Co., Ltd. Fetal Bovine Serum (10099141C) and DMEM/F-12 (1:1) (C11330500BT) basic medium were purchased from Grand Island Biological Company.
2.2 Preparation of JF
The medicinal materials of JF were obtained from Yunnan Ci Hui Pharmaceutical Co. Ltd. Except for 12 g of gancao, 36 g of each of the other ten medicinal herbs was measured, all materials were soaked in 4500 mL of distilled water for 30 min, the herb mixture was boiled for 20 min to collect the decoction and filtered. The JF water decoction was evaporated by a vacuum concentrator at 55 °C and concentrated to 15.5 mL. The concentrated liquid is freeze-dried, and the powder weight after drying is 6.98 g. After sealing, it is stored in a refrigerator at 4 °C for use.
2.3 Animal experiments
C57BL/6J male mice (20–22 g, SPF grade, 8 weeks old) and SD rats (200–220 g, SPF grade, 8 weeks old) were housed in a specific pathogen-free-grade animal facility. The animal studies were conducted with the Guidelines for Animal Experiments of Yunnan University of Chinese Medicine. The study protocol received approval from the Institutional Experimental Animal Ethics Committee of Yunnan University of Traditional Chinese Medicine (No. R-062023125; YNUTCM-XMSS-G-20250016). The mice were housed under a diurnal lighting condition (12/12-h light/dark cycle) for 1 week.
2.4 Determination of medicated serum components
16 mice were randomly divided into two groups (n = 8 each): JF and PIC + JF-treated groups, both groups were treated with 0.45 g JF extract/kg (equivalent to four times of the clinical dosage in human, which equivalent dose calculation is based on body surface area). Mice in the PIC + JF-treated group were administered 400 μg of PIC through the right nostril via slow dripping over 3 days to establish the ALI model (). 6 h post-exposure to PIC, the JF and PIC + JF-treated groups received subsequent administrations via gavage for a duration of 4 days 2 h following the last administration, the serum samples were collected and allowed to stand at room temperature for 30 min. Then the samples were centrifuged at 3,500 rpm for 10 min at 4 °C. Subsequently, 1 mL of serum was mixed with 4 mL of pre-cooled methanol and centrifuged at 4 °C at 12,000 rpm for 10 min. The supernatant was then dried using a nitrogen blowing instrument. Following this, 200 μL of pre-cooled methanol was added for re-dissolution, and the mixture was centrifuged at 4 °C at 12,000 rpm for 10 min. The resulting supernatant was used for the identification of small molecular substances.
2.5 Study on the effect of JF on ALI model mice
A total of 48 mice were divided into five groups: Control (Con, treated with saline by gavage), PIC (treated with saline by gavage), PIC + dexamethasone (PIC + Dex) (treated with Dex at a dosage of 5 mg/kg by gavage), PIC + JF-H (treated with 0.9 g JF extract/kg by gavage) and PIC + JF-L (treated with 0.45 g JF extract/kg by gavage). Mice in the PIC, PIC + Dex, PIC + JF-H, and PIC + JF-L groups were utilized to establish the ALI model, following the methodology described in Section 2.4. 6 h post-exposure to PIC, JF-treated groups received subsequent administrations at the specified doses for 4 days. The Dex-treated group received administrations prior to the initial modeling during sampling. Meanwhile, the Con and PIC groups were treated with saline. After 2 h after the last administration, the mice were euthanized after anesthesia via intraperitoneal injection of zoletil to harvest bio-samples.
2.6 Pulmonary function measure
Mice were anesthetized, and their tracheas were dissected for intubation. Started animal lung function detection system to detect lung function and set parameter: 0.2 mL max stroke volume; 30 cm H2O max mouth pressure; 0.75 mL deep inflation max volume; 40 cm H2O deep inflation max pressure; 140 breaths/min rate; 0 cm H2O peep.
2.7 Enzyme linked immunosorbent assay (ELISA)
Serum, nasal lavage fluid (NLF), and bronchoalveolar lavage fluid (BALF) were centrifuged at 3,000 rpm for 10 min. The resulting supernatant was then analyzed for the concentrations of TNF-α, IL-6, LDH and IL-18 using a test kit (Nanjing Jiancheng Bioengineering Institute (Nanjing, China)).
2.8 Histopathological analysis
The upper lobes of the left lung of mice were promptly fixed in 4% paraformaldehyde, dehydrated using a gradient of ethanol, and cleared with xylene. The tissue was then embedded in paraffin and sliced them into 4.0 μm thick slices. The slices containing the tissue sections were placed in an oven at 60 °C to dry. Subsequently, the sections were immersed in xylene for dewaxing and rehydrated using a gradient of ethanol. Hematoxylin and eosin (H&E) staining was conducted following the manufacturer’s specifications, and scanned with a scanning microscope (Kunming Naray Technology Co., Ltd., SQS-1000SQS-1000, China).
2.9 Transmission electron microscope analysis
The upper lobes of the left lung of mice were quickly fixed using an electron microscope fixative composed of 2.5% glutaraldehyde. The tissues were trimmed to 1 mm3 and fixed at 4 °C, then fixed in 1% osmic acid for 1.5 h. Subsequently, the samples were dehydrated using graded concentrations of ethanol and acetone, then, soaked, embedded, trimmed, sliced and stained, and observed under transmission electron microscope.
2.10 Transcriptomics analysis
Total RNA was extracted from the three individual lung tissues of Con, PIC, PIC + JF-L (PIC + JF) groups, using TRIzol®Reagent according the manufacturer’s instructions. RNA purification, reverse transcription, library construction and sequencing were performed at Shanghai Majorbio Bio-pharm Biotechnology Co., Ltd. (Shanghai, China). The RNA-seq transcriptome librariy was prepared following Illumina®Stranded mRNA Prep, Ligation (SanDiego, CA) using 1 μg of total RNA. The sequencing library was performed on DNBSEQ-T7platform (PE150) using DNBSEQ-T7RS Reagent Kit (FCLPE150) version3.0. To identify DEGs (differential expression genes) between three groups, the expression level of each transcript was calculated according to the transcripts per million reads (TPM) method. DEGs with |log2FC|≥1 and p-value < 0.05, were enriched in GO and KEGG at Bonferroni-corrected p-value <0.05 compared with the whole-transcriptome background.
2.11 Metabolomics analysis
Lung tissues (the source of bio-samples is the same as 2.10) were extracted by a mixture of methanol, acetonitrile and water (v/v/v, 2:2:1) (1 mL), and then placed for 1 h ultrasonic shaking in ice baths. The mixture was placed at −20 °C for 1 h and centrifuged at 14,000 g for 20 min at 4 °C. The supernatant was collected and dehydrated under vacuum conditions. Metabolomics profiling was analyzed using a UPLC-ESI-Q-Orbitrap-MS system (UHPLC, Shimadzu Nexera X2 LC-30AD, Shimadzu, Japan) coupled with Q-Exactive Plus (Thermo Scientific, San Jose, United States). For liquid chromatography (LC) separation, samples were analyzed using a ACQUITY UPLC® HSS T3 column (2.1 × 100 mm, 1.8 μm) (Waters, Milford, MA, United States). The flow rate was 0.3 mL/min and the mobile phase contained: A: 0.1% FA in water and B: 100% acetonitrile (ACN). The gradient was 0% buffer B for 2 min and was linearly increase to 48% in 4 min, and then up to 100% in 4 min and maintained for 2 min, and then decreased to 0% buffer B in 0.1 min, with 3 min re-equilibration period employed. The electrospray ionization (ESI) with positive-mode and negative mode were applied for MS data acquisition separately. The HESI source conditions were set as follows: Spray Voltage: 3.8 kv (positive) and 3.2 kv (negative); Capillary Temperature: 320 °C; Sheath Gas (nitrogen) flow: 30 arb (arbitrary units); Aux Gas flow: 5 arb; Probe Heater Temp: 350 °C; S-Lens RF Level: 50. The instrument was set to acquire over the m/z range 70–1050 Da for full MS. The full MS scans were acquired at a resolution of 70,000 at m/z 200, and 17,500 at m/z 200 for MS/MS scan. The maximum injection time was set to for 100 m for MS and 50 ms for MS/MS. The isolation window for MS2 was set to 2 m/z and the normalized collision energy (stepped) was set as 20, 30 and 40 for fragmentation. The raw MS data were processed using MS-DIAL for peak alignment, retention time correction and peak area extraction. And then, the PCA and PLS-DA were visualized the global metabolic changes, and utilized to select the differential metabolites based on VIP >1.0 (or |log2FC|≥0.58) combined with one way ANOVA (p < 0.05). The KEGG database were used to analyze the related metabolic pathways of differential metabolites.
2.12 Tissue immunofluorescence analysis
Quickly fixed the upper lobes of the left lung of mice in 4% paraformaldehyde, then embed them in paraffin and slice them into 3.0 μm thick sections. After dewaxing the addition of a pepsin repair solution, which was incubated at 37 °C for 30 min for antigen retrieval. A 2% Triton X-100 permeabilization solution was then added and incubated at room temperature for 20 min. Tissues were incubated with 5% bovine serum albumin at room temperature for 1 h, followed by overnight incubation at 4 °C with p-MLKL (1:200). Afterward, CoraLite 488-conjugated Goat Anti-Rabbit IgG (H + L) (1:500) was incubated at room temperature in dark for 1 h, and DAPI mounting solution was added for sealing. The tissues were subsequently observed under a fluorescence microscope.
2.13 Western blot (WB)
The lung tissues of mice were lysed in RIPA lysis buffer with Protein Phosphatase inhibitor. Protein concentration was measured by BCA Protein Assay Kit. Equal amounts of denatured protein were separated by SDS-PAGE and transferred to PVDF membranes (IPVH00010, Millipore, Billerica, United States). Blocked the membranes with 5% bovine serum albumin or 5% no-fat milk for 2 h, then incubate overnight with the following primary antibody at 4 °C: anti-MLKL (1:2000 dilution), anti-p-MLKL (1:2000 dilution), anti-GSDME (1:2000 dilution), and anti-β-actin (1:2000 dilution). The membranes were then incubated with corresponding secondary antibody for 1 h at room temperature. The bands were visualized using UVP gel imaging analysis system (BOX-F3, Beijing Staples Technology Co., Ltd., China) and quantified and analyzed using ImageJ software.
2.14 Molecular docking
To further elucidate the role of JF in mitigating ALI, the components in the medicated serum were molecularly docked with TNFR1 and TRPV1. The 3D structures of the primary ingredients of JF were downloaded from the PubChem platform, while TNFR1 and TRPV1 structures were obtained from the Worldwide Protein Data Bank (https://www.rcsb.org/) in PDB format. The large proteins and components were imported to AutoDockTools for hydrogenation, dehydration, and other pretreatments, followed by docking using AutoDock4. Subsequently, the results were visualized using Discovery Studio 2019.
2.15 Cell culture and treatment
Human lung adenocarcinoma cells A549 were obtained from the Beina Chuanglian Biotechnology Co., Ltd. (Beijing, China). A549 cells were cultured in DMEM medium containing 10% (v/v) fetal bovine serum and 1% (v/v) penicillin-streptomycin solution at 37 °C in a 5% CO2 atmosphere.
2.16 Preparation of JF medicated serum
Male SD rats were randomly divided into a control group and a JF treatment group. The control group received physiological saline via gavage, while the JF group was administered 0.68 g of JF extract (equivalent to four times of the clinical dosage in human)via gavage once daily for 7 consecutive days. 2 h after the final administration, the rats were anesthetized with isoflurane, and blood was collected from the abdominal aorta. The blood samples were placed in EP tubes and allowed to stand at room temperature for 30 min before being centrifuged at 3000 rpm for 10 min at 4 °C. The serum was inactivated in a water bath at 56 °C, aliquoted, and stored at −80 °C.
2.17 Cell viability assay
A549 cells in the logarithmic growth phase were seeded at a density of 4 × 104 cells/well in a 96-well culture plate and incubated in a carbon dioxide cell culture incubator. After cell adhesion, the cells were grouped and treated. The experiment was divided into four groups: normal group, model group (NEC), JF-containing serum group (with concentrations of 40%, 20%, 10%, 5%, 2.5%, 1.25%, and 0.625%), and Hes group (with concentrations of 328 μM, 164 μM, 82 μM, 41 μM, 20.5 μM, 10.25 μM, and 5.125 μM). The normal group was maintained under standard culture conditions, while the other groups were treated with a cell necroptosis inducer to establish a cell injury model. Following this, sample working solutions were added for a duration of 24 h. Subsequently, 20 μL of a 5 mg/mL MTS solution was added to each well and incubated at 37 °C for 2 h to ensure complete dissolution. The OD value was then measured at a wavelength of 490 nm using a multifunctional enzyme labeler.
2.18 Cellular immunofluorescence analysis
A549 cells were seeded at a density of 1 × 105 cells per well in a 12-well cell culture plate containing glass slides to ensure uniform distribution, and subsequently transferred to a CO2 incubator for cultivation. The experiment was divided into five groups: the normal group, the NEC group, the inhibitor group (Necrostatin-1 (NEC-1), 20 µM), the JF-containing serum group (2.5%, 5%), and the Hes group (41 μM, 20.5 µM). Except for the normal group, all other groups were treated with a cell necroptosis inducer to establish a cell injury model, alongside the addition of sample working solutions for 24 h. After 24 h of treatment, the medicated medium was removed from the wells, and the wells were washed with PBS. Subsequently, a cell fixation solution was added for 10 min at room temperature, followed by the addition of a pepsin repair solution, which was incubated at 37 °C for 30 min for antigen retrieval. A 2% Triton X-100 permeabilization solution was then added and incubated at room temperature for 20 min. Cells were incubated with 5% bovine serum albumin at room temperature for 1 h, followed by overnight incubation at 4 °C with p-MLKL (1:200). Afterward, CoraLite 488-conjugated Goat Anti-Rabbit IgG (H + L) (1:500) was incubated at room temperature in dark for 1 h, and DAPI mounting solution was added for sealing. The cells were subsequently observed under a fluorescence microscope, and fluorescent images were captured randomly.
2.19 Statistical analysis
All parameters were expressed as means ± SEM. Kruskal–Wallis test and analysis of variance (ANOVA) were performed to compare the means with the control group. Data were analyzed using GraphPad Prism9 software. Statistically significant differences were accepted at p < 0.05.
3 Results
3.1 Compounds of JF in serum of ALI mice
The results of identification of the transitional components in medicated serum of ALI model intervened by JF showed that a total of 305 components were detected in the negative ion mode, while 535 components were identified in the positive ion mode (Figure 2). By comparing these findings with existing literature and the TCMSP database, the sources of 34 components were analyzed, including 14 flavonoids, 7 coumarins, 8 terpenoids, 3 phenolic acids, 1 phenylpropanoid component and 1 other class components (Table 1). Among these, 10 components are derived from zhiqiao; 9 from fangfeng; 9 from qianhu, 9 from gancao, 8 from duhuo, 8 from qianghuo, 7 from chuanxiong, 4 from chaihu, 3 from jinjie and 1 from jiegeng. The medicinal materials with the most flavonoids was zhiqiao (6), while fangfeng and qianghuo both contained the most coumarins (6 each). In the medicated serum of normal mice after JF intervention, a total of 327 components were detected in the negative ion mode and 522 components were detected in the positive ion mode. Compared with the medicated serum of ALI mice with that of normal mice, there were 358 identical components in positive ion modes and 202 in negative ion modes. The same components were derived from 28 sources, with the content of 14 components increasing in the serum of ALI mice, 13 components decreasing, and the content of 1 component showing minimal difference (Figure 3).
FIGURE 2
TABLE 1
| No. | RT/Min | m/z | Adduct | Identification | Stem from | Classification |
|---|---|---|---|---|---|---|
| 1 | 7.558664 | 271.0897 | [M + H]+ | Alloimperatorin | fangfeng | Coumarins |
| 2 | 10.54755 | 347.1248 | [M + Na]+ | Glabridin | gancao | Flavonoids |
| 3 | 10.77748 | 169.0502 | [M + H]+ | Vanillic acid | fangfeng qianhu qianghuo | Phenolic acids |
| 4 | 12.36994 | 225.0756 | [M + H]+ | Sinapic acid | chuanxiong | Others |
| 5 | 12.68684 | 193.0497 | [M + H]+ | Scopoletin | fangfeng duhuo qianhu chuanxiong () qianhuo gancao chaihu | Coumarins |
| 6 | 13.00359 | 455.0945 | [M + Na]+ | Isovitexin | zhiqiao () | Flavonoids |
| 7 | 13.87097 | 447.0898 | [M + H]+ | Baicalin | chaihu | Flavonoids |
| 8 | 13.91276 | 285.0757 | [M + H]+ | Acacetin | jiegeng | Flavonoids |
| 9 | 14.10298 | 441.117 | [M + Na]+ | Liquiritin | gancao | Flavonoids |
| 10 | 14.1255 | 273.0775 | [M + H]+ | Naringenin | zhiqiao | Flavonoids |
| 11 | 14.18822 | 187.0399 | [M + H]+ | Psoralen | fangfeng duhuo qianhu | Flavonoids |
| 12 | 15.85314 | 285.0755 | [M + H]+ | Wogonin | fangfeng | Flavonoids |
| 13 | 16.1288 | 247.0981 | [M + H]+ | Marmesin | fangfeng duhuo qianhu zhiqiao () qianghuo | Coumarins |
| 14 | 17.66541 | 257.0793 | [M + H]+ | Liquiritigenin | gancao | Flavonoids |
| 15 | 17.81382 | 163.0388 | [M + H]+ | Umbelliferone | fangfeng () duhuo qianhu zhiqiao () qianghuo | Coumarins |
| 16 | 18.50737 | 293.0833 | [M + Na]+ | Isoimperatorin | fangfeng duhuo qianhu zhiqiao () qianghuo | Coumarins |
| 17 | 18.59222 | 223.0649 | [M + H]+ | Isofraxidin | fangfeng qianhu () qianghuo () | Coumarins |
| 18 | 19.35135 | 403.1383 | [M + H]+ | Nobiletin | zhiqiao | Flavonoids |
| 19 | 20.19486 | 373.1277 | [M + H]+ | Sinensetin | zhiqiao () | Flavonoids |
| 20 | 20.67813 | 153.1259 | [M + H]+ | (R)-(+)-Pulegone | jingjie chaihu | Terpenoids |
| 21 | 23.78942 | 471.3464 | [M + H]+ | Glycyrrhetic acid | gancao | Terpenoids |
| 22 | 28.82903 | 159.1164 | [M + Na]+ | Myrcene | jingjie chaihu chuanxiong zhiqiao | Terpenoids |
| 23 | 29.102 | 247.0882 | [M + H]+ | Columbianetin | qianghuo () duhuo () | Coumarins |
| 24 | 29.41642 | 191.1083 | [M + H]+ | Ligustilide | chuanxiong () | Terpenoids |
| 25 | 13.00773 | 609.1917 | [M-H]- | Hesperidin | zhiqiao jingjie | Flavonoids |
| 26 | 13.09256 | 193.0515 | [M-H]- | Ferulic acid | qianhu duhuo qianghuo chuanxiong () | Phenylpropanoids |
| 27 | 15.88148 | 137.0652 | [M-H]- | Salicylic acid | chuanxiong () | Phenolic acids |
| 28 | 17.06109 | 179.0353 | [M-H]- | Caffeic Acid | duhuo () chuanxiong | Phenolic acids |
| 29 | 17.35511 | 837.4006 | [M-H]- | Licoricesaponin G2 | gancao | Terpenoids |
| 30 | 17.60662 | 269.0457 | [M-H]- | Apigenin | zhiqiao | Flavonoids |
| 31 | 17.81761 | 821.4g023 | [M-H]- | Glycyrrhizin | gancao () | Terpenoids |
| 32 | 18.386 | 255.0669 | [M-H]- | Isoliquiritigenin | gancao | Flavonoids |
| 33 | 19.50174 | 487.3405 | [M-H]- | Asiatic acid | qianhu | Terpenoids |
| 34 | 23.53674 | 469.3346 | [M-H]- | Glycyrrhetinic Acid | gancao | Terpenoids |
Identification of transitional components in medicated serum of ALI model intervened by JF.
The component data without references were from TCMSP, database.
FIGURE 3
3.2 JF restored lung function and reduced cytokine contents in ALI mice
The results of lung function test in mice showed that JF could alleviate airway resistance and respiratory rate (Figure 4A). PIC increased the content of IL-6 and TNF-α in NLF, as well as the TNF-α content in BALF. Notably, JF was shown to reduce the content of IL-6 in NLF, the content of TNF-α in NLF, BALF and serum (Figures 4B–D).
FIGURE 4
3.3 JF improved the pathological damage of alveolar epithelial cells and mitochondria in ALI mice
H&E staining and transmission electron microscopy revealed that the lung tissue of Con group mice exhibited normal morphology, while the lung tissue of the PIC group mice displayed the thickened alveolar walls, infiltration inflammatory cells, necrotic exfoliated alveolar epithelial cells of type I, and type II alveolar epithelial cells osmiophilic multilamellar body vacuoles, mitochondrial membrane rupture. JF and Dex intervention significantly ameliorated the pathological changes in the lung tissue in ALI mice (Figures 4E–H).
3.4 RNA-seq analysis of the mechanism by which JF improves ALI
To explore the molecular basis and mechanism of JF in the treatment of ALI at the genetic level, this study performed transcriptomic sequencing analysis of lung tissues from the Con, PIC group and PIC + JF group in the animal model. According to the results, there were 631 DEGs identified between the PIC and Con groups (605 upregulated and 26 downregulated), and 1041 DEGs between the PIC + JF and PIC groups (280 upregulated and 761 downregulated) (Figures 5A,B). PPI network showed that TNF, IFN-γ, CXCL10 and STAT1 were the core DEGs between the PIC and Con groups, as well as the PIC + JF and PIC groups. Compared to Con group, the mRNA expression of these core DEGs was upregulated in the PIC group, while the PIC + JF intervention significantly downregulated the mRNA expression of these core DEGs compared to the PIC group (Figures 5C–E). All DEGs were functionally enriched, and 10 GO keywords were represented in the bubble plot. The findings revealed that the GO enrichment was primarily associated with immune response, defense response, and response to external biotic stimulus (Figures 5F,G). KEGG enrichment results showed that PIC treatment may affect cell processes such as phagosome and cellular senescence, JF intervention could influence cell processes such as phagosome, apoptosis, and necroptosis (Figures 5H,I).
FIGURE 5
3.5 Non-targeted metabolomics analysis of the mechanism by which JF improves ALI
PCA analysis was performed on all samples, in the PCA model, the distribution of quality control samples was concentrated, indicating that the sample analysis method had good reproducibility and high stability (Figure 6A). There was a significant difference between the PIC group and the Con group in the PC1 direction, indicating that there was a difference in the metabolic profile of the group. After JF intervention, the distribution of metabolites in mice lung tissue was significantly different from that in the PIC group in the PC1 direction (Figures 6B,C). A total of 421 DEMs were identified between the PIC and Con groups comprising 177 upregulated and 244 downregulated metabolites. Additionally, 170 DEMs (79 upregulated and 91 downregulated) were observed between the PIC + JF and PIC groups (Figures 6D,E). Classification of DEMs revealed that the primary regulated lipids and lipid-like molecules differed between the PIC vs. Con group and PIC + JF vs. PIC groups. The expression abundance of certain lipids and lipid-like molecules increased under PIC intervention, but decreased with JF intervention (Figures 6F–H). KEGG enrichment analysis indicated that PIC mainly affected the signaling pathways such as Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway and Oxidative phosphorylation. In contrast, after JF intervention, the primary pathways affected included Neuroactive ligand-receptor interaction, Arginine biosynthesis and Oxidative phosphorylation (Figures 6I,J). Further analysis of the neuroactive ligand-receptor interaction signaling pathway revealed that JF reduced the expression levels of NADA, Citric acid and Psychosine, while increasing the expression levels of ATP, L-Glutamate, L-Aspartate, β-Alanine and Taurine (Figure 6K).
FIGURE 6
3.6 JF protects ALI by reducing necroptosis
The DEGs and DEMs were utilized to construct a correlation expression heat map, which was subsequently integrated into the “Formula-DEGs-DEMs-pathway” diagram to validate the mechanistic relationship of JF. The role of JF in alleviating ALI was closely related to the regulation of necroptosis, neuroactive ligand-receptor interaction and TCA cycle (Figure 7A). Necroptosis could lead to cell membrane perforation, with p-MLKL and GSDME serving as typical perforins of the cell membrane. Animal immunofluorescence results showed that JF decreased the fluorescence intensity of p-MLKL in lung tissue (Figure 7B), as well as reduced the content of LDH and IL-18 in BALF (Figure 7C), and diminish the protein levels of p-MLKL, GSDME and the conversion rate of p-MLKL/MLKL (Figure 7D). Based on the findings from the omics analysis, it was speculated that TNFR1 and TRPV1 may also be the targets of JF to alleviate ALI. Therefore, the components in the medicated serum were docked with these targets. The results demonstrated that the 7 components represented by baicalin and hesperidin had higher binding affinity with TNFR1 and TRPV1 (Table 2; Figures 7E,F). The animal experiment results showed that necroptosis could occur in lung epithelial cells, so the study was further verified at the cellular level. The experimental results revealed that the IC50 values of JF medicated serum for normal cultured A549 cells and NEC-induced A549 cells were 20.48% and 49.59%, respectively. In contrast, the IC50 for Hes in both normal and NEC-induced A549 cells >328 μM (Figure 7G). Treatment with NEC significantly elevated the fluorescence level of p-MLKL in A549 cells. Following treatment with NEC-1, 5% JF medicated serum, as well as 20.5 μM and 42 μM of Hes, there was a significant decrease in the fluorescence level of p-MLKL in A549 cells (Figure 7H).
FIGURE 7
TABLE 2
| Serum components of JF | Affinity (kcal/mol) | |
|---|---|---|
| TNFR1 | TRPV1 | |
| Marmesin | −7.9 | −7.6 |
| Nobiletin | −8.1 | −7.3 |
| (R)-(+)-Pulegone | −5.3 | −6.7 |
| Hesperidin | −10.2 | −9.0 |
| Naringenin | −8.0 | −8.2 |
| Baicalin | −10.3 | −8.8 |
| Asiatic acid | −7.8 | −8.2 |
The docking results of the 7 active compounds of JF to the TNFR1 and TRPV1.
4 Discussion
ALI, one of the most common risk factors for ARDS, constitutes a significant global healthcare burden with persistently high morbidity and mortality rates. Despite extensive research, there are no specific pharmacotherapeutic interventions currently exist for ALI management. Therefore, it is crucial to identify effective therapies to reduce lung impairment by better understanding the underlying pathological molecular mechanisms. Recent studies have indicated that ALI is associated with multiple signaling pathways, including NF-κB, MAPK, and NLRP3 inflammasome activation (). This molecular complexity likely contributes to the limited efficacy of monotargeted therapeutic approaches. Notably, numerous studies suggest the beneficial effects of traditional Chinese medicine (TCM) prescriptions, characterized by their inherent multi-component and polypharmacological properties, which are particularly well-suited for treating ALI (). Such as Sini decoction and Xuebijing injection have demonstrated promising protective effects against ALI-induced pulmonary damage in preclinical studies through simultaneous modulation of multiple pathological pathways, TCM regimens ().
JF, an ancient Chinese herbal prescription traditionally utilized for treating upper respiratory infections, has demonstrated clinical efficacy in patients with ALI. In this study, we investigated the underlying mechanism of JF in improving ALI. Professor Wang () posits that only the ingredients absorbed in serum after oral administration of Chinese medicine prescriptions exert pharmacodynamic effects and are considered pharmacodynamically active. To investigate the pharmacodynamic material basis and mechanism of JF in treating ALI, we conducted serum component identification, transcriptomics and metabolomics following JF administration to ALI mice. We found that JF effectively mitigated lung tissue damage and improved lung function in a PIC-induced mouse ALI model. We identified 34 prototype components of JF in serum samples and found that most of these active components were derived from zhiqiao, fangfeng, qianhu, gancao, duhuo, qianghuo and chuanxiong. Therefore, these medicinal materials may play the same key role in treating ALI.
Upon invasion by respiratory viruses, there is a marked increase in the release of inflammatory cytokines that play a dualistic role. Elevated cytokine production compromises the integrity of the alveolar epithelial barrier, a crucial innate immune defense against pathogen invasion. This barrier, primarily composed of type I (ATI) pneumocytes interspersed with type II (ATII) cells, serves as the first line of defense within the alveoli. It is frequently the initial site of damage during lung injury. Disruption occurs during viral infections, leading to pulmonary edema via increased epithelial permeability and diminished surfactant production due to ATII cell injury (; ). NEC plays a crucial role in the damage of alveolar epithelial cells and the subsequent exacerbation of inflammatory responses (). NEC is a unique form of programmed cell death that occurs independently of cysteine-aspartic protease (caspase) activation. It is characterized by necrotic morphology, including cell swelling, organelle swelling, membrane perforation, followed by cell disintegration and the release of cellular contents. This process leads to extensive infiltration and activation of inflammatory cells, further amplifying the inflammatory response and aggravating lung injury (). TNFR1-driven excessive cell death serves as a powerful driving force for the initiation of inflammation, as it may disrupt biological barriers, resulting in microbial influx and further exacerbating the inflammatory response. Upon recognition of TNF-α by the TNFR1 on the cell membrane, an inflammatory response is triggered. The homotrimerization of TNFR1 leads to the formation of complex I, which can promote cell survival, apoptosis, or necroptosis, depending on the recruitment and ubiquitination of RIPK1. When the ubiquitination of RIPK1 is inhibited, complex I is released and recruits FADD, subsequently forming complex II. Complex II can mediate the activation of Caspase-8, which in turn activates the apoptotic signaling pathway. The FLIP protein, structurally related to but lacking the protease activity of Caspase-8, can form heterodimers that prevent Caspase-8-mediated apoptosis and NEC. The elimination of FADD, Caspase-8, or FLIP results in the spontaneous activation of RIPK3 and mixed lineage kinase domain-like protein (MLKL). In this context, RIPK1 and RIPK3 oligomerize through the RHIM domain to form necrosomes, which serve as conduits for necrotic signaling. Within necrosomes, MLKL is phosphorylated by RIPK3 and subsequently undergoes oligomerization, leading to its localization at the cell membrane. This process culminates in membrane rupture, resulting in the substantial release of intracellular contents and damage-associated molecular patterns (DAMPs) into the surrounding environment. This release triggers inflammation and ultimately leads to necroptotic cell death (; ; ).
Mitochondria, crucial organelles for cellular biosynthesis, energy production, and signal transduction, play a significant role in cellular adaptation to internal environmental homeostasis and the maintenance of normal physiological functions. Recent studies indicate that mitochondrial dysfunction contributes to the development of ALI. Mitochondria are the sites of vital life activities, where the tricarboxylic acid (TCA) cycle and oxidative phosphorylation occur, generating adenosine triphosphate (ATP) to supply energy for the entire cell. The TCA cycle oxidizes carbohydrates, fats, and proteins to produce energy. In eukaryotic systems, the TCA cycle occurs exclusively in the mitochondrial matrix, where aspartate or glutamic acid can be converted into α-ketoglutarate to participate in the cycle. Research indicates that glutamic acid exhibits excitotoxicity, activating the RIPK1/RIPK3/MLKL pathway (). Furthermore, necroptosis can be induced by citrate, an intermediate metabolite of the TCA cycle; when the cycle is inhibited, citrate accumulation may lead to cellular necroptosis. The TCA cycle repeatedly dehydrogenates to produce NADH and FADH2, providing sufficient reducing equivalents for the electron transport chain, which facilitates oxidative phosphorylation and ATP production (). ATP supplies energy to lung tissues, promoting the proliferation and differentiation of ATII into AECI to repair the alveolar epithelial barrier. During ALI (ALI), there is a disruption of Ca2+ homeostasis in the mitochondria of alveolar epithelial cells. Prolonged activation of TRPV1 can induce elevated Ca2+ levels, leading to its influx into the mitochondria and causing organelle damage. This effect triggers mitochondrial depolarization, disrupts the membrane potential, and induces the production of reactive oxygen species (ROS) and apoptosis. The disturbance of Ca2+ levels and the generation of ROS can activate NLRP3, subsequently recruiting Caspase-1/3 to cleave GSDMD/GSDME, forming membrane pores on the cell membrane and promoting the release of IL-1β and IL-18 (). Additionally, dysregulation of lipid metabolism plays a crucial role in the pathogenesis of ALI. For instance, studies demonstrated that imbalanced sphingolipid metabolism contributes to mitochondrial dysfunction and inflammatory amplification in an ALI model, while oxidized phospholipids promote pyroptosis through () the NLRP3 inflammasome pathway (; ; ). In summary, these studies highlight the therapeutic potential of targeting lipid metabolism reprogramming in ALI. In this study, we found that JF alleviated pulmonary inflammation, improved respiratory function parameters, preserved alveolar epithelial structure, and maintained mitochondrial integrity, thereby mitigating cell damage induced by pathogenic injury. JF and its active component, hesperidin, were shown to reduce NEC in alveolar epithelial cells. These findings establish a novel mechanism through which JF protects against ALI by targeting the NEC-mediated destruction of the alveolar epithelium, thereby highlighting its therapeutic potential for ALI intervention (Figure 8).
FIGURE 8
Despite the promising findings, our investigation was constrained by several limitations. Comprehensive metabolomics analysis indicated that JF exerts its effects by modulating the TCA cycle and enhancing mitochondrial oxidative phosphorylation, thereby counteracting cell NEC. However, the precise intracellular pathways mediating the anti-NEC actions remains unclear. Future studies should employ single-cell RNA sequencing and spatial metabolomics to dissect cell-type-specific responses and validate the in vivo relevance of TRPV1/TNFR1 interactions, which will allow us to better understand the regulatory mechanism of JF on NEC to improve ALI. This study conducts experiments on ALI caused by viral infections, however, it is important to note that numerous triggers for ALI exist, including bacterial infections, chemical irritants, and trauma, which suggests that the research scope may be relatively narrow. Therefore, employing a variety of models to investigate the role and mechanisms of JF is essential. Furthermore, integrating multidisciplinary perspectives from pathogen biology, immunometabolism, and clinical medicine is crucial to elucidate the complex mechanisms involved and to develop stratified intervention strategies that address the challenges posed by ALI diseases.
Statements
Data availability statement
The data presented in the study are deposited in the NCBI repository, accession number PRJNA1279349.
Ethics statement
The animal study was approved by Yunnan University of Chinese Medicine Animal Experiment Ethics Review Committee. The study was conducted in accordance with the local legislation and institutional requirements.
Author contributions
ZZ: Writing – original draft, Software, Formal Analysis, Data curation, Methodology, Validation, Visualization. BC: Software, Writing – original draft, Visualization, Conceptualization. RD: Project administration, Supervision, Writing – original draft, Methodology, Visualization, Conceptualization. GH: Data curation, Methodology, Validation, Writing – original draft. SX: Writing – original draft, Formal Analysis, Software. XZ: Validation, Investigation, Writing – original draft, Data curation. WW: Funding acquisition, Visualization, Project administration, Data curation, Supervision, Writing – review and editing, Investigation, Writing – original draft. XL: Resources, Writing – review and editing, Project administration, Data curation, Methodology, Investigation, Funding acquisition, Writing – original draft, Conceptualization.
Funding
The author(s) declared that financial support was received for this work and/or its publication. This work was supported by National Natural Science Foundation of China (82360803); Yunnan Provincial Science and Technology Department of Traditional Chinese Medicine Joint Special Major Projects (202001AZ070001-001); Yunnan Science and Technology Department Plan Project (202305AC160043); Shaojiang Song Expert Workstation of Yunnan Province (202305AF150030).
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2025.1649883/full#supplementary-material
References
1
BosL. D. J.WareL. B. (2022). Acute respiratory distress syndrome: causes, pathophysiology, and phenotypes. Lancet400 (10358), 1145–1156. 10.1016/S0140-6736
2
ChoiJ. P.KimY. S.TaeY. M.ChoiE. J.HongB. S.JeonS. G.et al (2010). A viral PAMP double-stranded RNA induces allergen-specific Th17 cell response in the airways which is dependent on VEGF and IL-6. Allergy65 (10), 1322–1330. 10.1111/j.1398-9995.2010.02369.x
3
ClementiN.GhoshS.De SantisM.CastelliM.CriscuoloE.ZanoniI.et al (2021). Viral respiratory pathogens and lung injury. Clin. Microbiol. Rev.34 (3), e00103–e00120. 10.1128/CMR.00103-20
4
CuiJ. Y.DengY. X.LiX. C.GaoL. Y.LiJ. R.et al (2025). Herbal-based xuebijing injection ameliorated vascular endothelial dysfunction via inhibiting ACLY/MYB/RIG-I axis in sepsis-associated lung injury. Phytomedicine140, 156573. 10.1016/j.phymed.2025.156573
5
FengQ.GuanY.HuangZ.YeS.ChengG.YaoJ.et al (2020). Study on active ingredients of jingfang baidu san for preventing COVID-19 based on network pharmacology and molecular docking. J. Pharm. Pract.38 (6), 485–538. 10.12206/j.issn.1006-0111.202005078
6
FengQ.SunC.LiS.LiX.XiaoM.ZhaoT.et al (2022). Anti-inflammatory mechanism of active ingredients in jingfang mixture based on network pharmacology and experimental verification. Chin. J. Chin. Mater Med.47 (20), 5481–5487. 10.19540/j.cnki.cjcmm.20220414.401
7
GuoH.GuanJ.WuX.WeiY.ZhaoJ.ZhouY.et al (2023). Peptide-guided delivery improves the therapeutic efficacy and safety of glucocorticoid drugs for treating acute lung injury. Mol. Ther.31 (3), 875–889. 10.1016/j.ymthe.2023.01.003
8
LiY.WangX.LiZ.ZhangJ.MengH.LvQ.et al (2017). Isolate and identify chemical constituents of methylene chloride and Ethyl acetate extract of saposhnikovia radix. Chin. J. Exp. Tradit. Med. Formulae23 (15), 60–64. 10.13422/j.cnki.syfjx.2017150060
9
LiuM. Y.LiH. B.YangR. L.JiD.XiaX. B. (2022). GSK872 and necrostatin-1 protect retinal ganglion cells against necroptosis through inhibition of RIP1/RIP3/MLKL pathway in glutamate-induced retinal excitotoxic model of glaucoma. J. Neuroinflammation19 (1), 262. 10.1186/s12974-022-02626-4
10
LongM. E.MallampalliR. K.HorowitzJ. C. (2022). Pathogenesis of pneumonia and acute lung injury. Clin. Sci. (Lond).136 (10), 747–769. 10.1042/CS20210879
11
LuY. T.ZengT. Y.ZhangH. M.LiY.ZhuX. L.LiuH. P.et al (2023). Nano-immunotherapy for lung cancer. Nano TransMed2 (1), e9130018. 10.26599/NTM.2023.9130018
12
MaL.YangJ. (2021). Research progress on chemical constituents and pharmacological activities of Notopterygii Rhizoma et Radix. Chin. Tradit. Herb. Drugs.52 (19), 6111–6120. 10.7501/j.issn.0253-2670.2021.19.034
13
MadsenH. B.DurhuusJ. A.AndersenO.StratenP. T.RahbechA.DeslerC. (2024). Mitochondrial dysfunction in acute and post-acute phases of COVID-19 and risk of non-communicable diseases. Npj Metab Health Dis2, 36. 10.1038/s44324-024-00038-x
14
MatthayM. A.ZemansR. L.ZimmermanG. A.ArabiY. M.BeitlerJ. R.MercatA.et al (2019). Acute respiratory distress syndrome. Nat. Rev. Dis. Prim.5 (1), 18. 10.1038/s41572-019-0069-0
15
MengJ.QiuZ.LiJ.WangY.TangQ. (2024). Textual research on key information of jingfang baidu powder. Chin. Tradit. Pat. Med.46 (64), 1262–1271. 10.3969/j.issn.1001-1528.2024.04.030
16
NailwalH.ChanF. K. (2019). Necroptosis in anti-viral inflammation. Cell Death Differ.26 (1), 4–13. 10.1038/s41418-018-0172-x
17
NiY. L.ShenH. T.SuC. H.ChenW. Y.Huang-LiuR.ChenC. J.et al (2019). Nerolidol suppresses the inflammatory response during lipopolysaccharide-induced acute lung injury via the modulation of antioxidant enzymes and the AMPK/Nrf-2/HO-1 pathway. Oxid. Med. Cell Longev.2019, 9605980. 10.1155/2019/9605980
18
PokharelM. D.Garcia-FloresA.MarcianoD.FrancoM. C.FinemanJ. R.AggarwalS.et al (2024). Mitochondrial network dynamics in pulmonary disease: bridging the gap between inflammation, oxidative stress, and bioenergetics. Redox Biol.70, 103049. 10.1016/j.redox
19
RenD.YangN.QianS.XieN.ZhouX.DuanJ. (2007). Chemical study on aerial parts of ligusticum chuanxiong. Chin. J. Chin. Mater Med.32 (14), 1418–1420.
20
RenW.GuoL.ZhangC. (2021). Research progress and predictive analysis of quality markers in rhizoma ligustici chuanxiong. World Sci. Technol-Mod Trad. Chin. Med.23 (9), 3307–3314. 10.11842/wst.20201029011
21
RyabkovaV. A.ChurilovL. P.ShoenfeldY. (2021). Influenza infection, SARS, MERS and COVID-19: cytokine storm-the common denominator and the lessons to be learned. Clin. Immunol.223, 108652. 10.1016/j.clim.2020.108652
22
ShakeriA.MasulloM.D'UrsoG.IranshahiM.MontoroP.PizzaC.et al (2018). In depth chemical investigation of Glycyrrhiza triphylla fisch roots guided by a preliminary HPLC-ESIMSn profiling. Food Chem.248, 128–136. 10.1016/j.foodchem.2017.12.031
23
SongZ.LiB.TianK.HongL.WuW.ZhangH. (2022). Research progress on chemical constituents and pharmacological activities of peucedani radix and peucedani decursivi radix. Chin. Tradit. Herb. Drugs.52 (3), 948–964. 10.7501/j.issn.0253-2670.2022.03.035
24
SunN.OgulurI.MitamuraY.YaziciD.PatY.BuX.et al (2024). The epithelial barrier theory and its associated diseases. Allergy79 (12), 3192–3237. 10.1111/all.16318
25
SunX.XiangH.LiuZ.XiaoH.LiX.GongW.et al (2024). Jingfang granules alleviates bleomycin-induced acute lung injury through regulating PI3K/Akt/mTOR signaling pathway. J. Ethnopharmacol.318 (Pt A), 116946. 10.1016/j.jep.2023.116946
26
TonnusW.BelavgeniA.BeuschleinF.EisenhoferG.FassnachtM.KroissM.et al (2021). The role of regulated necrosis in endocrine diseases. Nat. Rev. Endocrinol.17 (8), 497–510. 10.1038/s41574-021-00499-w
27
VintiñiE.HaroC.PalazonE.MedinaM. (2022). Nasal administration of a non-viable Lactobacillus casei to infant mice modulates lung damage induced by poly I:C and hyperreactivity in airways. Microbes Infect.24 (6-7), 104997. 10.1016/j.micinf.2022.104997
28
WangX. J. (2015). Methodology for systematic analysis of in vivo efficacy material base of traditional Chinese Medicine–Chinmedomics. China J. Chin. Mater Med.40 (1), 13–17. 10.4268/cjcmm20150103
29
WangH.ZhongG.ZhangS.HeJ.ZengJ. (2022). Research progress on chemical constituents and pharmacological effects of zhiqiao (aurantii fructus) and predictive analysis on quality markers. Chin. Arch. Tradit. Chin. Med.40 (9), 184–192. 10.13193/j.issn.1673-7717.2022.09.041
30
WangJ. Y.ZhuangH. W.LiC.CaiR. Q.ShiH. S.PangB. X.et al (2025). Ligustrazine nano-drug delivery system ameliorates doxorubicin-mediated myocardial injury via piezo-type mechanosensitive ion channel component 1-prohibitin 2-mediated mitochondrial quality surveillance. J. Nanobiotechnology23 (1), 383. 10.1186/s12951-025-03420-z
31
YangH.JiangH.TaoJ.ZhangC.XiongJ.YangJ.et al (2022). Mitochondrial citrate accumulation drives alveolar epithelial cell necroptosis in lipopolysaccharide-induced acute lung injury. Exp. Mol. Med.54 (11), 2077–2091. 10.1038/s12276-022-00889-8
32
YangL.YeZ. Y.LiL. S.ZhuangL.GuanJ. Z.GongW. P. (2024). Visualization analysis of research progress and trends in coexistence of lung cancer and pulmonary tuberculosis using bibliometrics. Med. Adv.2, 144–164. 10.1002/med4.58
33
YeonS. H.YangG.LeeH. E.LeeJ. Y. (2016). Oxidized phosphatidylcholine induces the activation of NLRP3 inflammasome in macrophages. J. Leukoc. Biol.101 (1), 205–215. 10.1189/jlb.3VMA1215-579RR
34
ZhangH.LiuJ.ZhouY.QuM.WangY.GuoK.et al (2022). Neutrophil extracellular traps mediate m6A modification and regulates sepsis-associated acute lung injury by activating ferroptosis in alveolar epithelial cells. Int. J. Biol. Sci.18 (8), 3337–3357. 10.7150/ijbs.69141
35
ZhaoY.HuJ.ZhangG.GuanY.ChengG.QuH. (2020). Origin and application of jingfang baidu powder. Glob. Tradit. Chin. Med.13 (11), 1996–2002. 10.3969/j.issn.1674-1749.2020.11.042
36
ZhouL.ZengJ. (2019). Research advances on chemical constituents and pharmacological effects of Angelica pubescens. Mod. Chin. Med.21 (12), 1739–1748. 10.13313/j.issn.1673-4890.20190321001
37
ZhuH.WangS.ShanC.LiX.TanB.ChenQ.et al (2021). Mechanism of protective effect of xuan-bai-cheng-qi decoction on LPS-induced acute lung injury based on an integrated network pharmacology and RNA-sequencing approach. Respir. Res.22 (1), 188. 10.1186/s12931-021-01781-1
Summary
Keywords
acute lung injury, alveolar epithelialbarrier, inflammation, Jingfang Baidu powder, Poly(I:C)
Citation
Zhu Z, Cui B, Dai R, Hu G, Xu S, Zhao X, Wang W and Li X (2026) Integrated metabolomic and transcriptomic analysis reveals the effects and mechanisms of Jingfang Baidu powder on acute lung injury. Front. Pharmacol. 16:1649883. doi: 10.3389/fphar.2025.1649883
Received
19 June 2025
Revised
09 December 2025
Accepted
15 December 2025
Published
09 January 2026
Volume
16 - 2025
Edited by
Wei Peng, Chengdu University of Traditional Chinese Medicine, China
Reviewed by
Meng-Yao Li, Shanghai Jiao Tong University, China
Zhenqi Wu, Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, China
Updates
Copyright
© 2026 Zhu, Cui, Dai, Hu, Xu, Zhao, Wang and Li.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xiufang Li, sofinelxf@163.com; Wenjing Wang, notoww@163.com
† These authors have contributed equally to this work
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.